secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2022-07-14T23:59:59+00:00
Accession:  0001200375-22-000025
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis cuts FY2022 revenue guidance to $135M-$141M; preliminary Q2 revenue ~$38M
--------------------------------------------------------------------------------

- Preliminary Q2 2022 total revenue ~$38M; full-year guidance reduced to $135M-$141M.
- Product revenue guidance unchanged at $112M-$118M; Pfizer product now at low end of $75M-$80M range, offset by other customers.
- Gross margin on product revenue maintained at 65% to 70%.
- CEO cites fewer new deals and lower-than-expected R&D revenue from existing customers as reason for reduction.
- Final Q2 results to be reported on August 4, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037522000025/0001200375-22-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037522000025/cdxs-20220714.htm
  HTML page:      https://secwatch.observer/filing/0001200375-22-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer